RFA
AMRX icon

Reilly Financial Advisors’s Amneal Pharmaceuticals AMRX Stock Holding History

Reilly Financial Advisors’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-500
Closed -$1K – 876
2019
Q3 		$1K Hold
500
– – ﹤0.01% 846
2019
Q2 		$4K Hold
500
– – ﹤0.01% 798
2019
Q1 		$7K Hold
500
– – ﹤0.01% 737
2018
Q4 		$7K Hold
500
– – ﹤0.01% 697
2018
Q3 		$11K Hold
500
– – ﹤0.01% 662
2018
Q2 		$8K Buy
+500
New +$8.78K ﹤0.01% 715

Other funds holding AMRX

FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Reilly Financial Advisors's AMRX Position: Q4 2019 in Review

Reilly Financial Advisors sold out of Amneal Pharmaceuticals (AMRX) in Q4 2019, closing a stake of 500 shares — an estimated $1K sold.

Reilly Financial Advisors first reported a position in AMRX in Q2 2018 and held it in 6 quarters. The position peaked at $11K in Q3 2018. 129 funds tracked by Wall St. Rank hold AMRX as of Q4 2019.

  • Reilly Financial Advisors reported no remaining Amneal Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Reilly Financial Advisors sold 500 Amneal Pharmaceuticals shares in Q4 2019, an estimated $1K.
  • Reilly Financial Advisors first reported a position in Amneal Pharmaceuticals in Q2 2018 and held it in 6 quarters.
  • Reilly Financial Advisors's Amneal Pharmaceuticals position peaked at $11K in Q3 2018.
  • 129 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q4 2019.

Based on Reilly Financial Advisors's 13F filing for Q4 2019, filed 16 Jan 2020.